Koi Chiho
   Department   University Hospital  Obstetrics and Gynecology, Clinical Departments
Article types journal article
Language English
Peer review Peer reviewed
Title In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor.
Journal Formal name:Oncology letters
Abbreviation:Oncol Lett
ISSN code:17921074/17921074
Domestic / ForeginForegin
Volume, Issue, Page 12(5),4263-4269頁
Author and coauthor Sakai Senna, Izumi Hiroto, Yoshiura Yukiko, Nakayama Yoshifumi, Yamaguchi Takahiro, Harada Yoshikazu, Koi Chiho, Kurata Hiroyuki, Morimoto Yasuo
Publication date 2016/11
Summary Aurora kinase B (AURKB) inhibitors are regarded as potential molecular-targeting drugs for cancer therapy. The present study evaluated the cytotoxic effect of a combination of AZD1152-hQPA, an AURKB inhibitor, and various anticancer agents on the HeLa human cervical cancer cell line, as well as its cisplatin-resistant equivalent HCP4 cell line. It was demonstrated that AZD1152-hQPA had an antagonistic effect on the cytotoxicity of cisplatin, etoposide and doxorubicin, but had a synergistic effect on that of all-trans-retinoic acid (ATRA), Am80 and TAC-101, when tested on HeLa cells. Cisplatin, etoposide and doxorubicin were shown to increase the cellular expression of AURKB, while ATRA, Am80 and TAC-101 downregulated its expression. These results suggested that AURKB expression is regulated by these anticancer agents at the transcriptional level, and that the level of expression of AURKB may influence the cytotoxic effect of AZD1152-hQPA. Therefore, when using anticancer agents, decreasing the expression of AURKB using a molecular-targeting drug may be an optimal therapeutic strategy.
DOI 10.3892/ol.2016.5156
PMID 27895801